See our updated news post for awardee details here.


On September 4, the A-T Children’s Project sent the below email to A-T researchers about available funds for a grant to test gene editing technologies to restore ATM protein function in cells from children with ataxia-telangiectasia.

Dear A-T Researchers,

We wanted to let you know of a funding opportunity through a partnership between the University of Pennsylvania’s Orphan Disease Center and the A-T Children’s Project.

One grant for $41,740 is available to support the testing of gene editing technologies such as base and prime editing, or dual-vector approaches that deliver large genes, to restore ATM protein function in cells from children with ataxia-telangiectasia.

The application deadline for Letters of Interest (LOI) is September 20, 2024. You can find the application on the Penn website. The RFA is at the same link (just scroll down to find A-T) and also at the bottom of this email.

Penn website: https://www.orphandiseasecenter.med.upenn.edu/grants/event-five-pk3yg-b7zlm-m4ag9-e5ysf-xywgg-mrtjk

Please feel free to share this information with respected colleagues who may bring innovative approaches to this scientific question. Thank you for your work which gives hope to all families coping with A-T!

All the best,

Jennifer

Jennifer Thornton, Executive Director


RFA for A-T:
Ataxia-Telangiectasia (A-T): Team Derek’s Dreams and the A-T Children’s Project have provided a $41,740 grant to support the testing of gene editing technologies such as base and prime editing, or dual-vector approaches that deliver large genes, to restore ATM protein function in cells from children with ataxia-telangiectasia. The tested methodologies must have a clear path by which promising results can subsequently be advanced into preclinical and clinical development.

If you are an A-T or ATM researcher and would like to be added to our mailing list, please email us at info@atcp.org. Thank you!

Related News

Jan 23 @ 10:05 am

Press Release from Business Wire about A-T Trial Results

IntraBio announces positive trial results of Levacetylleucine for the treatment of ataxia-telangiectasia.

more
Jan 23 @ 10:05 am

Encouraging News from an A-T Clinical Trial

IntraBio announced positive results from its pivotal Phase III clinical trial of a drug for children and adults

more
Jan 23 @ 10:05 am

Heading into 2026 with big momentum for A-T

The A-TCP is excited about how much possibility this moment holds for A-T research.

more
Jan 23 @ 10:05 am

Breaking News about A-T and GRP94

A-TCP funds a researcher who sheds new light on A-T and on how the ATM gene functions in

more